Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | CEL | P19835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95364 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL207351 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL21831413 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL866108 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL21831588 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL866938 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL867290 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL22524 | 0.97 | — | — | |
| SCHEMBL29156058 | 0.94 | CYP1A2 (0.50) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL25313563 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | QUADREL S.R.L. (IT) | 2023-11-16 | — | — | US | disclosed |
| EP-4216960-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | Quadrel S.r.l. (IT) | 2023-08-02 | — | — | EP | disclosed |
| WO-2020204188-A1 | PRODUCTION METHOD FOR CYCLIC OLEFIN COPOLYMER | ポリプラスチックス株式会社 | 2020-10-08 | — | — | WO | disclosed |
| US-20200179914-A1 | METHOD FOR PRODUCING CATALYST | POLYPLASTICS CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| WO-2020071494-A1 | METHOD FOR PRODUCING CYCLIC OLEFIN POLYMER | ポリプラスチックス株式会社 | 2020-04-09 | — | — | WO | disclosed |
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| EP-2207773-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-07-21 | — | — | EP | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2089373-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009057811-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-1957073-A2 | MEDICINAL DRUG | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008044667-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | WO | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | CYP1A2 79/4885SIGMAR1 52/4885EPHX1 666/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | CYP1A2 3133/4885SIGMAR1 549/4885EPHX1 4412/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | CYP1A2 979/4885SIGMAR1 21/4885EPHX1 894/4885 |
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | PIGO, PIGS, AGPS | CYP1A2 1194/4885SIGMAR1 4672/4885EPHX1 615/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | CYP1A2 100/4885SIGMAR1 136/4885EPHX1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.